Considerations related to radical fimbriectomy as an option in prophylaxis against serous carcinoma development

Research has shown that papillary tubal hyperplasia may lead to the development of serous cancer in the fallopian tubes, ovaries, and peritoneum. According to numerous studies, opportunistic bilateral salpingectomy significantly reduces the risk of developing ovarian cancer. Recent data proves that radical fimbriectomy involving the tube and fimbrio-ovarian junction lowers ovarian, fallopian, and peritoneal serous cancer incidence. Risk-reducing salpingo-oophorectomy (RRSO) remains the gold-standard in prophylaxis regarding ovarian cancer in carriers of BRCA mutations, other options may exist - radical fimbriectomy which preserves function of the ovaries, observation in dedicated centers, and removal of the ovaries upon menopause.

Radical fimbriectomy; Risk-reducing salpingo-oophorectomy (RRSO) serous cancers in BRCA mutations

[1] Ness RB., Dodge RC., Edwards R.P., Baker J.A., Moysich K.B.: “Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer”. Ann. Epidemiol., 2011, 21, 188.

[2] Yoon S.H., Kim S.N., Shim S.H., Kang S.B., Lee S.J.: “Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: A meta-analysis”. Eur. J. Cancer, 2016, 55, 38.

[3] Falconer H., Yin L., Grönberg H., Altman D.: “Ovarian cancer risk after salpingectomy: a nationwide population-based study”. J. Natl. Cancer Inst., 2015, 107, pii: dju410.

[4] Chen Y., Du H., Bao L., Liu W.: “Opportunistic salpingectomy at benign gynecological surgery for reducing ovarian cancer risk: a 10- year single centre experience from China and a literature review”. J. Cancer, 2018, 9, 141.

[5] Kurman R.J., Shih IeM.: “Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications”. Int. J. Gynecol. Pathol., 2008, 27, 151.

[6] Kurman RJ., Vang R., Junge J,. Hannibal C.G., Kjaer S.K., Shih IeM.: “Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis”. Am. J. Surg. Pathol., 2011, 35, 1605.

[7] Moss EL., Evans T., Pearmain P., Askew S., Singh K., Chan K.K., et al.: “Should all cases of high-grade serous ovarian, tubal, and primary peritoneal carcinomas be reclassified as tubo-ovarian serous carcinoma?” Int. J. Gynecol. Cancer, 2015, 25, 1201.

[8] Meinhold-Heerlein I., Fotopoulou C., Harter P., Kurzeder C., Mustea A., Wimberger P., Hauptmann S.: “The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications”. Arch. Gynecol. Obstet., 2016, 293, 695.

[9] Alvarez R.M., Vazquez-Vicente D.: “Fertility sparing treatment in borderline ovarian tumours”. Ecancermedicalscience, 2015, 9, 507.

[10] Hasdemir P.S., Guvenal T.: ‘Borderline ovarian tumours: A contemporary review of clinicopathological characteristics, diagnostic methods and therapeutic options”. J. BUON., 2016, 21, 780.

[11] Piek JM., van Diest PJ., Zweemer RP., Jansen J.W., Poort-Keesom R.J., Menko F.H., et al.: “Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer”. J. Pathol., 2001, 195, 451.

[12] Leblanc E., Narducci F., Farre I., Peyrat J.P., Taieb S., Adenis C., Vennin P.: “Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development”. Gynecol. Oncol., 2011, 121, 472.

[13] Leblanc E., Narducci F., Hudry D., Bresson L., Charvolin J.Y., Ferron G., et al.: “First results of a prospective National Controlled Study: Prophylactic radical fimbriectomy (NCT01608074) in women with a hereditary familial risk of breast/ovarian cancer. Tolerance and pathological findings”. J. Clin. Oncol., 2018, Abstract No 5574. ASCO Annual Meeting Proceedings.